Phase 2B Double-blind Placebo-controlled Crossover Study Evaluating the Efficacy of Intravenous Fosaprepitant for Chemotherapy-induced Nausea and Vomiting (CINV) Associated With High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Metastatic Renal Cell Carcinoma

Trial Profile

Phase 2B Double-blind Placebo-controlled Crossover Study Evaluating the Efficacy of Intravenous Fosaprepitant for Chemotherapy-induced Nausea and Vomiting (CINV) Associated With High-dose Interleukin-2 (HD IL-2) for Metastatic Melanoma and Metastatic Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Fosaprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms HD IL-2/Emend
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 20 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top